Email:
Tel:

AVPR2-Targeted Drug Discovery Services

Whatever information you want about AVPR2-targeted drug discovery, you can find it here. For more details or related services, please feel free to contact us.

Introduction

Introduction

Vasopressin receptor 2 (V2R) is also known as arginine vasopressin receptor 2 (officially called AVPR2). This gene encodes the vasopressin receptor, type 2, also known as the V2 receptor, which belongs to the seven-transmembrane-domain G protein-coupled receptor (GPCR) superfamily, and couples to Gs thus stimulating adenylate cyclase. The subfamily that includes the V2 receptor, the V1a and V1b vasopressin receptors, the oxytocin receptor, and isotocin and mesotocin receptors in non-mammals, is well conserved, though several members signal via other G proteins. All bind similar cyclic nonapeptide hormones. The V2 receptor is expressed in the kidney tubule, predominantly in the distal convoluted tubule and collecting ducts, where its primary property is to respond to the pituitary hormone arginine vasopressin (AVP) by stimulating mechanisms that concentrate the urine and maintain water homeostasis in the organism. When the function of this gene is lost, the disease Nephrogenic Diabetes Insipidus (NDI) results. The V2 receptor is also expressed outside the kidney although its tissue localization is uncertain. When these 'extrarenal receptors' are stimulated by infusion of a V2 selective agonist (dDAVP), a variety of clotting factors are released into the bloodstream. The physiologic importance of this property is not known - its absence does not appear to be detrimental in NDI patients. The gene expression has also been described in fetal lung tissue and lung cancer associated with alternative splicing. [provided by RefSeq, Jul 2008]

AVPR2-Targeted Drug Discovery Services

Direction of Drugs Discovery

Direction of Drugs Discovery

• AVPR2 Modulator
• AVPR2 Agonist
• AVPR2 Inhibitor
• AVPR2 Antagonist
• Developing New Clinical Effects on AVPR2 from Existing Drugs

Drugs

Drugs

• AVPR2 Modulator- Conivaptan
• AVPR2 Agonist- Desmopressin, ASP-7035, OPC-51803, OX 19
• AVPR2 Inhibitor- Mozavaptan, ATOSIBAN, SSR149415, VA-106483
• AVPR2 Antagonist- Tolvaptan, SPD-556, JTV-605, CL-385004

What We Offer

Target Testing Target Testing

CD BioSciences provides AVPR2 testing services by WB, Flow, IF, ICC, or IHC assay. The results of AVPR2 testing are used to evaluate the activities of candidates against AVPR2 or targeted diseases. You can choose one or more testing ways to detect the level of AVPR2 according to your experiment.

Hit Identification Hit Identification (show more)

The goal of early drug discovery is to find novel lead compounds that have the desired potency, selectivity, and ADMET properties for pre-clinical evaluation.
CD BioSciences offers hit identification services to make your finding of targeted compounds more successful and faster.
• High-Throughput Screening
• AVPR2-Targeted in Silico Virtual Screening
• Fragment-Based Screening
• High-Content Screening

Antibody Drugs Development Services Antibody Drugs Development Services (show more)

Antibody drugs exhibit many incomparable advantages, such as high specificity, affinity, and efficiency, which is an emerging direction on targeted drug development. CD BioSciences provides comprehensive services on AVPR2-targeted antibody drugs development with professional technology, extensive experience, and advanced equipment.
• Antibody Preparation Services
• Phage Display Services
• Antibody-Drug Conjugates
• Bispecific Antibody Services
• Antibody Humanization Services

Pharmacological Experiment Pharmacological Experiments (show more)

We will create a specific experimental plan according to your requirements, including but not limited to
• Pharmacokinetics / Pharmacodynamics
• Pharmacodynamics
• Pharmacokinetics
• Safety Pharmacology

Disease Models Screening Disease Models Screening (show more)

We will create specific disease models to accelerate your targeted drug discovery project, including but not limited to
• Diseases—Acute diabete complication, polyuria, enuresis, hyponatraemia, etc.
CD BioSciences will establish the specific disease models according to your requirements to evaluate the inhibitory activity of your candidates targeted AVPR2. We have various cell lines and the species of our animal models cover rats, mice, rabbits, dogs, and non-human primates.

Inquire Us Inquire Us

References

  1. 1. Stelzer G.; et al. The GeneCards Suite: From Gene Data Mining to Disease Genome Sequence Analysis , Current Protocols in Bioinformatics(2016), 54:1.30.1 - 1.30.33.doi: 10.1002 / cpbi.5.
    2. Wishart DS; et al. DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008 Jan;36(Database issue): D901-6.
    3. Y. Zhou; et al. Therapeutic target database update 2022: facilitating drug discovery with enriched comparative data of targeted agents. Nucleic Acids Research. 50(D1): 1398-1407 (2022). PMID: 34718926.
  • Tel:
  • Email:
Copyright © CD BioSciences. All Rights Reserved.
Top